U.S. Software Stock News

If you are wondering whether TEGNA at around $19.55 is quietly underpriced or already fairly valued, you are in the right place to unpack what the numbers are really saying. The stock has inched up 0.8% over the last week and 4.1% year to date, and while the 7.6% 1 year and 58.0% 5 year returns are solid, the slightly negative 1 month move of -1.9% hints that the market is still undecided about its next big swing. Recent headlines have focused on TEGNA's ongoing role as a major local TV...

Wondering if Roblox at around $99 a share is still a smart buy after its huge run, or if the easy money has already been made? This article will walk through what the numbers really say about its value. The stock has climbed 68.3% year to date and 76.0% over the last year, even after a recent 7.3% pullback over the past month and a 5.7% rebound in just the last week. This signals that investors are still willing to pay up for growth. Recent headlines have focused on Roblox expanding beyond...

IRADIMED (IRMD) just handed investors a year end gift by approving a special 0.50 dollar per share cash dividend that sits on top of its regular payouts and signals confidence in future cash generation. See our latest analysis for IRADIMED. The move comes after IRADIMED highlighted its growth story at recent investor conferences, and the strong backdrop shows in the numbers, with the share price up sharply this year and multi year total shareholder returns suggesting that momentum is still...

Market context and recent performance Regeneron Pharmaceuticals (REGN) has been drifting lower in the past week, even after a solid run over the past 3 months. This has prompted investors to revisit whether the recent pullback offers a reasonable entry point. See our latest analysis for Regeneron Pharmaceuticals. The recent 7 day share price pullback sits against a still impressive 90 day share price return of 24.6 percent. However, a softer 1 year total shareholder return of negative 10.5...

If you are wondering whether Hecla Mining is still worth buying after its huge run up, you are not alone. This article is going to unpack what the current price really implies about future returns. The stock has slipped about 2.1% over the last week, but it is still up 13.2% over the past month, 223.2% year to date, and 191.2% over the last year. This naturally raises questions about how much upside is left versus how much risk has crept in. Behind these big moves, investors have been...

S&P Global Indices recently announced that Hawaiian Electric Industries was added to the S&P SmallCap 600 Index as part of its latest quarterly rebalancing, reflecting the utility’s qualification under the index’s size and liquidity criteria. This mechanical inclusion, which often attracts buying from index-tracking funds, highlights how index membership can influence trading activity without altering the company’s underlying business fundamentals. We’ll now examine how Hawaiian Electric’s...

If you have ever looked at McDonald's and wondered whether a global fast food icon can still be a value play, you are exactly who this breakdown is for. The stock has quietly climbed to around $310.79, with returns of 3.3% over the last week, 3.7% over the last month, 6.2% year to date, 5.8% over 1 year, and 62.1% over 5 years, which naturally raises questions about how much upside is left. Recent headlines have focused on McDonald's ongoing menu innovation and digital initiatives, from...

Wondering if Baidu is a bargain or a value trap at today’s price? Let’s break down what the market is really pricing in and where the opportunity might lie. Baidu’s share price has climbed 4.2% over the last week and is up a hefty 49.9% year to date, even though the last 30 days have been slightly negative at -1.6%. Over the past year it is still sitting on a 38.9% gain, despite only a modest 3 year return of 4.0% and a 5 year loss of -33.2%. Recent moves have been driven by growing optimism...

Robinhood Markets (HOOD) has quietly turned into a big winner for patient investors, with the stock up around 164% over the past year as the business scales and profitability improves. See our latest analysis for Robinhood Markets. That momentum has been fueled by improving fundamentals and growing engagement on the platform, with a robust year to date share price return of 244.09% and a powerful 1-year total shareholder return of 263.25% signaling that sentiment has meaningfully shifted in...

Why Coca-Cola's Valuation Deserves a Closer Look Coca-Cola has long been viewed as a classic defensive stock, but its current share price is raising fresh questions about whether investors are paying up for safety or getting a fair deal. To figure that out, it can help to break down its value using a few different lenses rather than relying on reputation alone. On the surface, Coke still appears to be the steady compounder it has long been, with dependable cash flows and one of the strongest...

If you are wondering whether Thermo Fisher Scientific is still a smart buy at around $563 a share, or if the easy gains are already behind it, this breakdown will help you evaluate what you might really be paying for. The stock is up 7.8% year to date and 5.7% over the last year, but that climb has cooled recently, with a 2.3% dip over the past month and a 3.0% slide in the last week, suggesting that market sentiment is in flux. Investors have been reacting to a mix of headlines around...

FinVolution Group (FINV) is back in the spotlight after fresh coverage underscored its shift to a capital light consumer credit facilitator model, stronger international momentum and management’s renewed confidence in revenue growth into 2025. See our latest analysis for FinVolution Group. Despite the fresh enthusiasm, the stock’s 90 day share price return of negative 32.46% and year to date share price return of negative 23.89% show sentiment is still resetting. At the same time, the five...

Power Solutions International recently reported that its pivot toward higher-growth emission-certified power systems, especially for data centers, has driven substantial increases in 2025 net sales and net income, supported by a revised revolving credit facility and removal of prior going-concern uncertainty. This shift positions the company as a cash-generative integrator benefiting from surging on-site generation needs tied to AI and data-center expansion, creating a clearer operational...

Wondering if Vistra is still worth buying after its massive run, or if most of the upside is already baked into the price? Here is a closer look at what the current share price implies about its future. After an explosive multiyear climb of 613.3% over 3 years and 891.3% over 5 years, the stock has cooled off recently, slipping 4.5% in the last week and 13.7% over the past month, while still sitting on a 10.1% gain year to date and 17.1% over the last year. These moves are happening against...

If you are wondering whether D.R. Horton at around $149 a share is a bargain or a value trap right now, you are not alone, and this breakdown is designed to address exactly that question. The stock is up 121.2% over five years and 76.2% over three years, but more recently it is down 5.7% over the last week, up 3.2% over the last month, and only 8.5% higher year to date. This suggests the market is rethinking its risk and growth expectations. Those swings are happening against a backdrop of...

Coeur Mining (CDE) just kicked off its biggest exploration push at Palmarejo since 2012, and early drilling hits at La Unión, Camuchín, Hidalgo, and San Miguel are quietly reshaping the long term resource picture. See our latest analysis for Coeur Mining. That exploration update lands after a huge run, with Coeur’s share price now at $16.07 and a powerful year to date share price return of 159.19 percent alongside a 1 year total shareholder return of 129.9 percent. This is signalling momentum...

Earlier this week, Erie Indemnity reported third-quarter 2025 results with earnings per share of US$3.50 beating expectations, while revenue came in slightly below analyst estimates and trading conditions were broadly weak. Despite these pressures, the company remains profitable and has maintained an uninterrupted dividend record for 30 consecutive years, underscoring its income-focused appeal. With the share price recently experiencing a 6.27% weekly decline, we’ll consider how the revenue...

Wondering if EPAM Systems at around $208 is a recovery story or a value trap? You are not alone, and this piece is going to dig into what the current price really implies. The stock has bounced about 7.8% over the last week and 18.6% over the past month, even though it is still down 9.2% year to date and 16.8% over the last year, with a much steeper slide of 42.9% over three years and 36.2% over five years. Much of this recent volatility has been tied to shifting sentiment around IT services...

AMC Entertainment Holdings (AMC) has cashed in most of its Hycroft Mining stake, securing roughly $24.1 million in proceeds while keeping a smaller equity position and warrants, signaling a renewed focus on its core theater business. See our latest analysis for AMC Entertainment Holdings. The move to exit most of Hycroft comes after a tough stretch for shareholders, with a year to date share price return of negative 43.28 percent and a 1 year total shareholder return of negative 48.76...

Ensign Group (ENSG) has quietly outperformed many healthcare peers this year, so the stock now invites a closer look at whether its strong long term returns still leave room for further upside. See our latest analysis for Ensign Group. Recent trading has cooled slightly, with a modest pullback from recent highs even as Ensign holds near $174.14. However, the 90 day share price return and multi year total shareholder returns still point to sustained momentum rather than a reversal. If Ensign’s...

If you are wondering whether Summit Therapeutics is still worth a closer look after its big run, or if you would just be buying into yesterday's hype, this article will walk you through what the current price really implies. Summit has cooled off recently, with the stock up 1.4% over the last week and 1.8% over the past month. However, that sits on top of a 469.6% gain over three years and 235.6% over five years, even though the 1 year return is slightly negative at 0.8%. Those moves have...

Recently, analysts have raised their earnings estimates for AvePoint, and the stock has received a top Zacks Rank, reflecting stronger confidence in its profit outlook. This shift follows an earlier post-earnings setback highlighted by Voya Investment Management, underscoring how changing sentiment and short interest trends can rapidly reshape perceptions of AvePoint’s prospects. Next, we’ll examine how this renewed analyst optimism around AvePoint’s earnings outlook influences the company’s...

Lands' End (LE) has just posted Q3 2026 results with revenue of about $317.5 million and basic EPS of $0.17, putting a clear profit on the board for the quarter. The company has seen quarterly revenue hold around the low $300 million mark over the last few periods, while basic EPS has swung from losses of roughly $0.27 and $0.17 earlier in 2026 to a modest profit this quarter, setting up a story that is increasingly about how much of that top line can translate into sustainable margins. See...

Bristol-Myers Squibb (BMY) has quietly pushed higher over the past month, even as its longer term returns remain underwhelming. That mix of recent momentum and lagging history is exactly what makes the stock interesting now. See our latest analysis for Bristol-Myers Squibb. Over the past year, Bristol-Myers Squibb’s share price return has been negative, but the recent 1 month and 3 month share price gains suggest sentiment is cautiously improving as investors reassess its pipeline and...